GE HealthCare Technologies Inc. GEHC
NasdaqMedical devicesFinancials to Sep 30, 2026 · Updated Nov 11, 2026
Moat ranks
Balance sheet
| $B | Dec 31 | Sep 30 |
|---|---|---|
| Cash | 4.5 | 2.8 |
| Securities | 0.0 | 0.0 |
| Debt | 10.0 | 10.0 |
| Net cash | -5.5 | -7.1 |
| Equity | 10.4 | 11.6 |
- Debt / EBITDA
- 2.84×
- Debt / equity
- 0.86×
- Diluted shares
- 453M
- Book value / share
- $25.64
- Price / book
- 3.3×
- Net cash / share
- −$15.78
- Market cap
- $37.8B
- Enterprise value
- $45.0B
Per-share record
Key indicators
| Indicator | Latest | Vs year ago | Last 8 quarters |
|---|---|---|---|
| Revenue growth | 7.2% | +1.4 pts | |
| Operating margin | 14.6% | +1.9 pts | |
| FCF margin | 14.4% | +5.0 pts | |
| Capex / revenue | 2.1% | -0.1 pts | |
| Organic orders growth | +4% | – | |
| Book-to-bill | 1 | – | |
| Order backlog | $23.7B | – | |
| Service sales · 6/30/26 | $1.9B | +8% | |
| AIS revenue · 6/30/26 | $3.8B | +8% |
Margins and growth from reported quarters; company KPIs as reported in results releases.
About GEHC
GE HealthCare sells imaging systems, patient-care equipment and diagnostic drugs. Its latest recast quarter puts 71.3% of segment revenue in Advanced Imaging Solutions, 12.8% in Patient Care Solutions and 15.9% in Pharmaceutical Diagnostics.
- Service Field Network
Large installed base supported by a global field service organization; uptime-critical assets drive service contract attachment and parts revenue.
- Data Workflow Lockin
Imaging software, AI applications, and data integration services embed GEHC into radiology workflows; lifecycle software upgrades reduce willingness to switch OEMs.
- Scope Economies
AIS combines radiology, specialized ultrasound and procedural guidance, allowing imaging, ultrasound and software capabilities to be reused across modalities and procedure-room offerings.
- Installed Base Consumables
Monitoring fleets drive recurring revenue via proprietary parameters, sensors, and a broad catalog of consumables and service contracts.
- Oct 5, 2026
GE HealthCare agreed to buy SOFIE for $945M cash, adding 15 US manufacturing sites and 21 cyclotrons if the transaction closes in the first half of 2027.
- Sep 23, 2026
GE HealthCare expanded research with Mass General Brigham on generative AI for radiation-therapy planning, testing an extension of its clinical software capabilities without a commercial product approval.
- Sep 22, 2026
GE HealthCare raised its quarterly dividend from $0.035 to $0.04 per share, increasing its regular shareholder payout while funding acquisitions.
- Sep 22, 2026
GE HealthCare appointed Pascal Desroches to its board effective January 4, 2027, adding a finance executive during its acquisition and portfolio review program.
- Sep 15, 2026
GE HealthCare launched CareIntellect for Operations with two first health-system adopters, extending its hospital workflow software portfolio.
Ownership
Go deeper on GEHC
- Compare stock research toolsFundamentals, valuation and screening platforms for GEHC.19 tools
- See GEHC's price chartNo price chart here yet. See price history and indicators.17 tools
- Read GEHC's earnings callsTranscripts and audio of results calls, with management's own words.15 tools
- Investing tool dealsCurrent discounts on research, charting and tracking tools.98 deals
On this page
Financial record
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | Trend | Change 2019–25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Per share ($) | ||||||||||
| Revenue | – | – | 38.73 | 40.40 | 42.69 | 42.86 | 45.03 | 47.76 | – | |
| Cash flow | – | – | 3.54 | 4.65 | 4.59 | 4.25 | 4.34 | 5.33 | – | |
| Earnings | – | – | 4.91 | 4.18 | 3.43 | 4.34 | 4.55 | 4.75 | – | |
| Free cash flow | – | – | 2.99 | 3.97 | 3.74 | 3.38 | 3.29 | 4.17 | – | |
| Capex | – | – | 0.55 | 0.68 | 0.84 | 0.87 | 1.05 | 1.16 | – | |
| Dividends | – | – | 0.00 | 0.00 | 0.09 | 0.12 | 0.14 | 0.14 | – | |
| Book value | – | – | 36.69 | 20.61 | 15.57 | 18.40 | 22.66 | 25.64 | – | |
| Diluted shares (M) | – | – | 454 | 454 | 458 | 459 | 458 | 453 | – | |
| Totals ($B) | ||||||||||
| Revenue | 16.6 | 17.2 | 17.6 | 18.3 | 19.6 | 19.7 | 20.6 | 21.6 | +3.7%/yr | |
| Operating income | 2.1 | 2.7 | 2.8 | 2.5 | 2.4 | 2.6 | 2.8 | 2.9 | +4.5%/yr | |
| Net income | 1.7 | 2.0 | 2.2 | 1.9 | 1.6 | 2.0 | 2.1 | 2.2 | +3.9%/yr | |
| Free cash flow | 1.7 | 1.4 | 1.4 | 1.8 | 1.7 | 1.6 | 1.5 | 1.9 | -1.6%/yr | |
| Buybacks | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.3 | – | |
| Dividends | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | – | |
| Net cash | – | 1.0 | 0.5 | -6.8 | -6.9 | -6.1 | -5.5 | -7.1 | – | |
| Margins & returns (%) | ||||||||||
| Gross margin | 39.4 | 39.4 | 40.8 | 39.1 | 40.5 | 41.7 | 40.0 | 39.9 | +0.6 pts | |
| Operating margin | 12.8 | 15.8 | 15.9 | 13.8 | 12.5 | 13.3 | 13.4 | 13.3 | +0.6 pts | |
| Net margin | 9.9 | 11.7 | 12.7 | 10.3 | 8.0 | 10.1 | 10.1 | 10.0 | +0.2 pts | |
| FCF margin | 10.0 | 8.3 | 7.7 | 9.8 | 8.8 | 7.9 | 7.3 | 8.7 | -2.7 pts | |
| ROIC | – | 14.1 | 12.4 | 11.1 | 12.3 | 12.9 | 12.4 | 11.0 | – | |
| Return on equity | 7.7 | 13.6 | 13.4 | 20.3 | 22.0 | 23.6 | 20.1 | 18.5 | +12.4 pts | |
| R&D % of revenue | 5.0 | 4.7 | 4.6 | 5.6 | 6.2 | 6.7 | 6.1 | 6.1 | +1.1 pts | |
| Stock pay % of revenue | 0.4 | 0.5 | 0.4 | 0.4 | 0.6 | 0.6 | 0.6 | 0.7 | +0.2 pts | |
| Capex % of revenue | 2.0 | 1.5 | 1.4 | 1.7 | 2.0 | 2.0 | 2.3 | 2.4 | +0.3 pts | |
Change uses 2019 and 2025 only: compound annual growth for amounts, points for margins and returns, and the change in amount for net cash. A dash means no 2019 base. Trend shows the fiscal years.
Moat
Moat scorecard
- Strength
- Confidence
- Structure
- Oligopoly
- Durability
- durable
- Trajectory
- stable
- Pricing power
- moderate
- Advanced Imaging Solutions (AIS)71.3%3 claims
- Patient Care Solutions (PCS)12.8%2 claims
- Pharmaceutical Diagnostics (PDx)15.9%3 claims
Moat claims
- Applies to
- Advanced Imaging Solutions (AIS)
- Confidence
- Durability
- durable
- Trajectory
- stableas of Oct 8, 2026
Large installed base supported by a global field service organization; uptime-critical assets drive service contract attachment and parts revenue.
First-half service sales rose 7.6%, but acquisitions contributed and service renewal rates are not disclosed; the service footprint remains a durable advantage.
- Organic orders growth+4%
- Book-to-bill1
- Order backlog$23.7B
- Service sales$1.9B+8%
- AIS revenue$3.8B+8%
- AIS segment EBIT$525M+15%
- Field service engineers~8,900+7%
- Right-to-repair regulations expanding third-party access
- Independent service organizations (ISOs) undercut OEM service pricing
- Increased remote diagnostics reducing differentiation of onsite service
- FilingGE HealthCare Technologies Inc. FY2025 Form 10-KFeb 4, 2026
- FilingGE HealthCare Technologies Inc. FY2025 Form 10-K (Risk Factors)Feb 4, 2026
- Applies to
- Advanced Imaging Solutions (AIS)
- Confidence
- Durability
- medium
- Trajectory
- stableas of Oct 8, 2026
Imaging software, AI applications, and data integration services embed GEHC into radiology workflows; lifecycle software upgrades reduce willingness to switch OEMs.
Intelerad adds outpatient software workflows, but GE has not disclosed retention gains and the July PACS correction shows that data migration still creates safety risks.
- Service sales$1.9B+8%
- AIS revenue$3.8B+8%
- AIS segment EBIT$525M+15%
- Open standards and vendor-neutral archives weaken lock-in
- Cloud-native imaging IT vendors displace incumbent stacks
- Interoperability mandates reduce switching frictions
- Applies to
- Advanced Imaging Solutions (AIS)
- Confidence
- Durability
- medium
- Trajectory
- stableas of Oct 8, 2026
AIS combines radiology, specialized ultrasound and procedural guidance, allowing imaging, ultrasound and software capabilities to be reused across modalities and procedure-room offerings.
AIS generated $525M of Q2 segment EBIT across complementary imaging products; the new combined structure has not yet proved additional cross-selling benefits.
- Organic orders growth+4%
- Book-to-bill1
- Order backlog$23.7B
- AIS revenue$3.8B+8%
- AIS segment EBIT$525M+15%
- Modular best-of-breed systems displace integrated suites
- Open integration standards reduce ecosystem advantage
- Hospital consolidation strengthens bargaining power
- FilingGE HealthCare Technologies Inc. FY2025 Form 10-K (Business - AVS)Feb 4, 2026
- FilingGE HealthCare Form 10-Q (quarter ended Jun 30, 2026)Jul 29, 2026
- Applies to
- Patient Care Solutions (PCS)
- Confidence
- Durability
- durable
- Trajectory
- narrowingas of Oct 8, 2026
Monitoring fleets drive recurring revenue via proprietary parameters, sensors, and a broad catalog of consumables and service contracts.
PCS revenue fell 13.3% and Q2 segment EBIT turned to a $26M loss, showing that its installed base did not protect results from fulfillment failures.
- PCS revenue$675M-13%
- PCS segment EBIT−$26M-143%
- Third-party compatible disposables/sensors reduce OEM capture
- Hospital procurement standardization squeezes consumables pricing
- Device connectivity standards reduce proprietary parameter advantage
- FilingGE HealthCare Technologies Inc. FY2025 Form 10-K (Business - PCS)Feb 4, 2026
- Applies to
- Patient Care Solutions (PCS)
- Confidence
- Durability
- medium
- Trajectory
- narrowingas of Oct 8, 2026
Clinical decision and workflow software aggregates device data across care settings, increasing integration and change-management costs for hospitals.
The Portrait software correction requires alternative patient monitoring during updates, weakening the reliability that supports embedded clinical workflows.
- Service sales$1.9B+8%
- PCS revenue$675M-13%
- PCS segment EBIT−$26M-143%
- Vendor-neutral monitoring platforms integrated with EHRs displace point solutions
- Cybersecurity incidents and order-summary software errors reduce trust in connected platforms
- Interoperability requirements reduce switching costs
- FilingGE HealthCare Technologies Inc. FY2025 Form 10-K (Business - PCS)Feb 4, 2026
- FilingGE HealthCare Technologies Inc. FY2025 Form 10-K (Business - PCS)Feb 4, 2026
- Applies to
- Pharmaceutical Diagnostics (PDx)
- Confidence
- Durability
- medium
- Trajectory
- stableas of Oct 9, 2026
Reliable, timely global supply of contrast media and radiopharmaceuticals is critical; capacity, logistics, and quality systems create operational barriers and customer preference for dependable suppliers.
PDx organic sales rose 12.3% in the first half, but the $945M SOFIE purchase remains conditional and new Cork capacity is planned for late 2027; stronger supply protection is not yet demonstrated.
- PDx revenue$843M+16%
- PDx segment EBIT$250M+17%
- Diagnostic-agent procedures140,000,000
- Manufacturing disruptions (quality issues, plant outages)
- Input constraints (APIs, radioisotopes) and logistics shocks
- Government price controls or tender reforms
- FilingGE HealthCare Technologies Inc. FY2025 Form 10-K (Business - PDx)Feb 4, 2026
- NewsGE HealthCare invests $138M in Cork contrast media facilityJan 31, 2025
- FilingGE HealthCare Technologies Inc. FY2025 Form 10-K (Business - PDx)Feb 4, 2026
- Applies to
- Pharmaceutical Diagnostics (PDx)
- Confidence
- Durability
- durable
- Trajectory
- stableas of Oct 8, 2026
Strict regulation and lifecycle monitoring (marketing authorizations, pharmacovigilance, inspections) raise barriers to entry and favor scaled incumbents with mature quality systems.
PDx remains subject to manufacturing and marketing approvals; the $843M Q2 revenue base demonstrates commercial scale but does not prove a unique regulatory advantage over peers.
- PDx revenue$843M+16%
- PDx segment EBIT$250M+17%
- Diagnostic-agent procedures140,000,000
- Regulatory changes increasing cost or delaying launches
- Safety concerns driving labeling restrictions or product withdrawal
- Applies to
- Pharmaceutical Diagnostics (PDx)
- Confidence
- Durability
- medium
- Trajectory
- stableas of Oct 8, 2026
Combining imaging equipment, agents, cyclotrons and visualization software lets GE offer integrated products and share research across imaging methods and diseases.
PDx Q2 revenue reached $843M alongside imaging equipment and software, but agents also work with rival systems and no cross-selling rate is disclosed.
- Organic orders growth+4%
- Book-to-bill1
- Order backlog$23.7B
- PDx revenue$843M+16%
- PDx segment EBIT$250M+17%
- Diagnostic-agent procedures140,000,000
- Antitrust scrutiny or bundling restrictions
- Customers prefer best-of-breed sourcing across vendors
- FilingGE HealthCare Technologies Inc. FY2025 Form 10-K (Business - PDx)Feb 4, 2026
Profile change log
- Oct 9, 2026 · analyst revision
Clarified the July 29 AIS event as the first combined segment-results disclosure. The segment combination itself was announced on April 29, so its announcement now has a separate dated event.
- Oct 9, 2026 · business change
GE HealthCare announced that Imaging and Advanced Visualization Solutions would combine into AIS, aligning imaging hardware and software under one segment; later quarterly disclosures recast the comparative figures.
- Oct 9, 2026 · analyst revision
Added the disclosed but unquantified IRS tax-indemnity exposure to the investment debate. The resolved PDx supplier issue and contract-settlement income remain in reported earnings because separate amounts are not disclosed.
- Oct 9, 2026 · business change
GE HealthCare expanded research with Mass General Brigham on generative AI for radiation-therapy planning, testing an extension of its clinical software capabilities without a commercial product approval.
- Oct 9, 2026 · business change
GE HealthCare reduced 2026 adjusted EPS guidance from $4.95-$5.15 to $4.80-$5.00 as memory, oil and freight inflation increased, while keeping its organic revenue growth outlook.
- Oct 9, 2026 · analyst revision
Changed the PDx supply trajectory from widening to stable because higher sales and pending capacity do not prove stronger supply protection. Added competitor operating evidence and legal and safety developments, restored sourced major suppliers without market-share estimates, and corrected the CFO board-appointment date from August 18 to August 13.
- Oct 9, 2026 · business change
GE HealthCare appointed Pascal Desroches to its board effective January 4, 2027, adding a finance executive during its acquisition and portfolio review program.
- Oct 9, 2026 · business change
GE HealthCare announced StarGuide GX SPECT/CT following CE Mark; US FDA clearance remains pending, so US commercial access is conditional.
- Oct 9, 2026 · business change
Health Canada dated a Type II Centricity High Acuity Anesthesia recall for errors in order summaries and printed records, adding a clinical-software reliability risk.
- Oct 9, 2026 · business change
GE HealthCare introduced three Vivid cardiovascular ultrasound systems, broadening cardiac imaging and procedural workflows across care settings.
- Oct 9, 2026 · business change
GE HealthCare entities and other defendants asked the US Supreme Court to review the Atchley anti-terrorism case; the petition does not resolve the underlying claims or damages.
- Oct 9, 2026 · business change
GE HealthCare bought icometrix for about $98M net cash plus possible earn-outs, adding brain-imaging software for integration with its MRI systems.
- Oct 9, 2026 · business change
GE HealthCare committed $138M to expand its Cork contrast-agent factory, targeting 25 million additional annual doses by the end of 2027.
- Oct 9, 2026 · business change
GE bought BK Medical for $1.466B, adding surgical ultrasound and guidance to the portfolio and explaining most of the 2021 acquisition cash outflow.
- Oct 8, 2026 · analyst revision
Added all eight moat trajectories, segment end markets, operating KPI history, management and an investment debate. PCS advantages are narrowing under sourced fulfillment and software-reliability pressures; claim strengths and all profile timestamps stay unchanged. Removed unsupported full-market leaders and sizing from the shared imaging profile. Separation costs recur through 2026 and remain in reported earnings.
- Oct 8, 2026 · business change
GE HealthCare agreed to buy SOFIE for $945M cash, adding 15 US manufacturing sites and 21 cyclotrons if the transaction closes in the first half of 2027.
- Oct 8, 2026 · business change
GE HealthCare raised its quarterly dividend from $0.035 to $0.04 per share, increasing its regular shareholder payout while funding acquisitions.
- Oct 8, 2026 · business change
GE HealthCare launched CareIntellect for Operations with two first health-system adopters, extending its hospital workflow software portfolio.
- Oct 8, 2026 · business change
GE HealthCare received CE Mark for Photonova Spectra, expanding access to its photon-counting CT system in European markets.
- Oct 8, 2026 · business change
FDA classified the Portrait software instruction correction as Class II; customers must provide alternative monitoring during software updates.
- Oct 8, 2026 · business change
GE HealthCare's board appointed William Grogan as CFO effective September 14, placing a new finance leader in charge of cost control and acquisition funding; the company announced the appointment on August 18.
- Oct 8, 2026 · business change
GE HealthCare issued a Centricity PACS data-migration correction because images could attach to the wrong patient, creating safety and workflow trust risks.
- Oct 8, 2026 · business change
GE HealthCare published its first combined AIS segment results and announced a strategic review of PCS after a $26M quarterly loss, focusing capital allocation on its stronger businesses.
- Oct 8, 2026 · business change
GE HealthCare bought Intelerad for $2.293B net cash, expanding outpatient imaging software and increasing acquired-intangible amortization.
- Oct 8, 2026 · business change
GE HealthCare bought the remaining Nihon Medi-Physics stake for $271M net cash, expanding Japanese radiopharmaceutical production and recording a $97M stake remeasurement gain.
- Oct 8, 2026 · business change
GE HealthCare became an independent listed company, assuming stand-alone costs, debt and transferred pension obligations.
- Oct 8, 2026 · business change
GE sold its BioPharma business to Danaher, removing a business whose sale gain distorts historical consolidated earnings.
Industry & peers
Peer map
Global diagnostic imaging and image-guided therapy
Global diagnostic imaging, specialized ultrasound and image-guided procedure systems, with related service, software and enterprise imaging workflows. Excludes general patient monitoring, diagnostic agents and standalone therapeutic radiation systems.
- GE HealthCare
- Siemens Healthineers
- Philips
- Canon
- United Imaging
| Stocks | Moat | Gross m. | Op. m. | |
|---|---|---|---|---|
| GEHC | 81 | 39.9% | 13.3% | |
| Industry median | 14 | 75 | 52.1% | 13.3% |
| Sector median | 55 | 76 | 61.5% | 17.3% |
| All stocks median | 398 | 76 | 53.1% | 20.0% |
Moat medians cover every stock. Margin medians count only stocks with collected numbers and need at least three.
Drivers & risks
- Ageing populations and chronic disease increase diagnostic scans and minimally invasive procedures.
- Hospital staff shortages raise demand for faster scans, remote servicing and integrated clinical workflows.
- AI reconstruction, spectral CT and helium-free MRI can support replacement demand and premium product mix.
- Hospital financing costs and public budgets control the timing of large equipment orders.
- Insurance reimbursement for scans and procedures affects equipment utilization and the cash hospitals can reinvest.
- Hospital tenders and strong GE HealthCare, Siemens, Canon and local competition constrain prices.
- China purchasing delays and preference for domestic equipment can weaken multinational demand.
- Tariffs, currency translation and scarce technical inputs can reduce profit even when comparable demand grows.
- Patient-safety recalls, cybersecurity failures and strict approval rules can delay launches and damage service trust.
- Open data standards and independent service firms reduce the value customers place on a single-vendor software or repair system.
Bulls & bears
Can imaging service and diagnostic-agent growth convert into cash and lasting profit while GE repairs PCS and integrates its software acquisitions?
Arguments
What to watch
- 1Organic orders, backlog and AIS service revenue
- 2PCS revenue and segment EBIT after fulfillment recovery
- 3PDx organic revenue, operating cash flow and total debt
Next check: Q4 2026 results: test current customer demand, cash conversion, current guidance and material later management or regulatory events.
Sources: company filings and dated sources collected for Find My Moat; market cap as of Nov 10, 2026. Not investment advice.
Free to reuse, commercially too, with a credit link. See the data license.
Moat Score 81/100 by <a href="https://www.findmymoat.com/stocks/XNAS:GEHC">Find My Moat</a> (as of September 2026)Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.